当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Cobos-Campos Raquel and Lasso-Varela Aurora*
Objectives: There is no consensus about the implications of the delay of RT beginning in the incidence of recurrences and mortality of patients with breast cancer. We carried out a retrospective study to assess if the delay of RT beginning can increase the risk of recurrences and mortality.
Methods: We conducted a retrospective observational study including women with a primary diagnosis of breast cancer stage I or II, between January 2003 and December 2008. All patients received surgery, RT and adjuvant chemotherapy, and were followed for a 5 years after diagnosis. Data was obtained from the medical records. The incidence of recurrence and mortality was assessed by logistic regression adjusting for variables that might affect the prognosis of the disease (age, hormone receptors, lymph node involvement, type of chemotherapy, hormone therapy, etc.), and was expressed with the Odds Ratio (OR).
Results: We have not found association between the risk of relapse and delay of RT starting (OR 2.819; 95% CI 0.635-12.506, p=0.173). We have not found association between the risk of mortality by all cause and delay of RT starting (OR 0.993; 95% CI 0.210-4.407, p=0.961).
Conclusions: In view of the results obtained, delaying the start of RT does not seem to increase the risk of recurrences or mortality.